Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tracheobronchial Polyflex stents for the management of benign refractory hypopharyngeal strictures.

World journal of gastroenterology·2012
Same author

A novel exonic rearrangement affecting MLH1 and the contiguous LRRFIP2 is a founder mutation in Portuguese Lynch syndrome families.

Genetics in medicine : official journal of the American College of Medical Genetics·2011
Same author

Abdominal haematoma--a mesotherapy complication.

Acta dermato-venereologica·2005
Same author

E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients.

European journal of cancer (Oxford, England : 1990)·2004
Same author

Schistosomal colonic polyposis.

Gastrointestinal endoscopy·2003
Same author

Endoscopic ultrasonography in multiple lymphomatous polyposis.

Journal of clinical gastroenterology·2002

Related Experiment Videos

Pantoprazole: a proton pump inhibitor.

Luis Moreira Dias1

  • 1Médico Gastroenterologista, Porto, Portugal. l.md@clix.pt

Clinical Drug Investigation
|November 27, 2009
PubMed
Summary

Pantoprazole, a proton pump inhibitor (PPI), effectively reduces gastric acid and is well-tolerated for acid-related disorders. It shows comparable efficacy to other PPIs and is valuable for managing gastroesophageal reflux disease and NSAID-induced injury.

Area of Science:

  • Pharmacology
  • Gastroenterology

Background:

  • Proton pump inhibitors (PPIs) are key in managing acid-related gastrointestinal disorders.
  • Pantoprazole is a PPI known for its specific binding and reduced activation in acidic environments.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of pantoprazole in treating acid-related disorders.
  • To compare pantoprazole's effectiveness against other treatments like other PPIs and H2 receptor antagonists.

Main Methods:

  • Review of clinical studies on oral pantoprazole (20 or 40 mg/day) for short-term and long-term treatment.
  • Assessment of pantoprazole's efficacy in gastro-oesophageal reflux disease and NSAID-related injury.
  • Evaluation of drug-drug interactions and use in pediatric populations.

Related Experiment Videos

Main Results:

  • Pantoprazole demonstrated comparable efficacy to omeprazole, lansoprazole, and esomeprazole in treating gastro-oesophageal reflux disease.
  • It showed greater efficacy than histamine type 2 receptor antagonists.
  • Pantoprazole is effective in preventing NSAID-related gastric injury and is well-tolerated in adults and adolescents.

Conclusions:

  • Pantoprazole is a valuable and well-tolerated option for managing various acid-related disorders.
  • Its long duration of action and lack of identified drug-drug interactions contribute to its therapeutic utility.